Literature DB >> 11278645

Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells.

P Li1, S V Nicosia, W Bai.   

Abstract

PTEN/MMAC1/TEP-1 (PTEN) tumor suppressor and androgen receptor play important roles in prostatic tumorigenesis by exerting opposite effects on homeostasis of prostatic epithelium. Here, we describe a mutual repression and selective dominance between PTEN and the androgen receptor (AR) in the growth and the apoptosis of prostatic cancer cells. On the one hand, PTEN and an inhibitor of phosphoinositide 3-kinase repressed the transcriptional activity of the AR as well as androgen-induced cell proliferation and production of prostate-specific antigen. On the other hand, androgens protected prostate cancer cells from PTEN-induced apoptosis in an AR-dependent manner. Whereas the repression of the transcriptional activity of the AR by PTEN is likely to involve the down-regulation of AKT, androgens protected prostate cancer cells from PTEN-induced apoptosis without an effect on AKT activity, demonstrating a differential involvement of AKT in the interaction between PTEN and the AR. Our data suggest that the loss of PTEN function may induce tumorigenesis through unopposed activity of the AR as well as contribute to the resistance of prostate cancers to androgen ablation therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278645     DOI: 10.1074/jbc.M010226200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR.

Authors:  Pengfei Li; Heehyoung Lee; Shaodong Guo; Terry G Unterman; Guido Jenster; Wenlong Bai
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

Review 2.  AR-dependent phosphorylation and phospho-proteome targets in prostate cancer.

Authors:  Varadha Balaji Venkadakrishnan; Salma Ben-Salem; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2020-06       Impact factor: 5.678

3.  A novel function of the Fe65 neuronal adaptor in estrogen receptor action in breast cancer cells.

Authors:  Yuefeng Sun; Ravi Kasiappan; Jinfu Tang; Panida L Webb; Waise Quarni; Xiaohong Zhang; Wenlong Bai
Journal:  J Biol Chem       Date:  2014-03-11       Impact factor: 5.157

4.  The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.

Authors:  Sanjay N Mediwala; Huiying Sun; Adam T Szafran; Sean M Hartig; Guru Sonpavde; Teresa G Hayes; Perumal Thiagarajan; Michael A Mancini; Marco Marcelli
Journal:  Prostate       Date:  2012-07-20       Impact factor: 4.104

5.  The androgen receptor induces integrin α6β1 to promote prostate tumor cell survival via NF-κB and Bcl-xL Independently of PI3K signaling.

Authors:  Laura E Lamb; Jelani C Zarif; Cindy K Miranti
Journal:  Cancer Res       Date:  2011-02-10       Impact factor: 12.701

6.  Basic science of hormonal therapy for prostate cancer.

Authors:  D M Peehl
Journal:  Rev Urol       Date:  2001

7.  FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment.

Authors:  Qiuping Ma; Wei Fu; Pengfei Li; Santo V Nicosia; Guido Jenster; Xiaohong Zhang; Wenlong Bai
Journal:  Mol Endocrinol       Date:  2008-12-12

8.  Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation.

Authors:  Heehyoung Lee; Wenlong Bai
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

9.  Conditionally immortal ovarian cell lines for investigating the influence of ovarian stroma on the estrogen sensitivity and tumorigenicity of ovarian surface epithelial cells.

Authors:  Feng Jiang; Beatriz O Saunders; Edward Haller; Sandra Livingston; Santo V Nicosia; Wenlong Bai
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Jul-Aug       Impact factor: 2.416

10.  Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer.

Authors:  Rile Li; Sibel Erdamar; Hong Dai; Thomas M Wheeler; Anna Frolov; Peter T Scardino; Timothy C Thompson; Gustavo E Ayala
Journal:  Hum Pathol       Date:  2007-06-26       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.